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Abstract. The immune status in patients with liver cirrhosis 
is generally impaired due to concomitant hypersplenism. As 
the spleen is the largest lymphoid organ, deleterious events 
resulting from splenectomy are of concern in these patients. 
However, the immunological consequences after splenectomy 
have not yet been fully elucidated. In the present study, the 
immune status after splenectomy was comprehensively 
examined. Splenectomy was performed in 11 patients with 
liver cirrhosis and hypersplenism, and the immune status in 
peripheral blood was examined and compared before and at 1, 
3 and 6 months after splenectomy. Splenectomy significantly 
lowered the neutrophil-to-lymphocyte ratio, due to a surge in 
lymphocytes in the peripheral circulation at 3 and 6 months 
after splenectomy. The frequency of cluster of differentia-
tion (CD)4+ T cells decreased after splenectomy, whereas the 
frequency of CD8+ T cells increased. Notably, the frequencies 
of the naïve and central memory subsets of CD4+ and CD8+ 
T cells decreased, whereas those of the effector memory 
subset trended upward. In addition, the frequencies of other 
immune cells such as γδ T cells, natural killer T cells and 
natural killer cells transiently increased, while inhibitory cells 
such as regulatory T cells and myeloid-derived suppressor 
cells significantly decreased. T‑cell responses to viral‑ and 
tumor‑associated antigens increased after splenectomy in five 
of eight and two of five patients, respectively. To the best of 
our knowledge, this is the first study to precisely examine the 
drastic changes of immunological phenotypes in peripheral 
blood after splenectomy in patients with cirrhosis. Our find-
ings suggested that splenectomy in patients with cirrhosis may 
ameliorate the impaired immune status, possibly by reducing 
suppressive cells and enhancing the effector cell population 
and function, which could, at least in part, explain the mecha-
nisms responsible for the clinical benefits of splenectomy.
Introduction
Patients with liver cirrhosis are generally regarded as immu-
nocompromised (1). Not only does bacterial infection develop 
in 14.5 to 34.0% of patients with liver cirrhosis (2), but 
community-acquired infections are also frequently observed 
in patients with more advanced liver cirrhosis. Because the 
spleen is the largest lymphoid organ in the body with concen-
trated amounts of T and B cells, macrophages, and dendritic 
cells, splenectomy in patients with cirrhosis has produced 
concern over decreased tumor immunity and an elevated risk 
of infection, such as overwhelming pneumococcal sepsis (3-5).
Thrombocytopenia has been known to be an important 
factor that interferes with treatment of hepatocellular carci-
noma and chronic liver diseases (6). We previously reported 
that splenectomy in patients with advanced cirrhosis corrected 
thrombocytopenia, improved liver function, reduced portal 
venous pressure, and allowed prolonged management of 
hepatocellular carcinoma (HCC) and hepatitis C virus (HCV) 
infection (7). Other researchers have also described the 
clinical benefits of splenectomy in the management of portal 
hypertension (8,9), HCC (10), and living-donor liver transplan-
tation (11) among patients with liver cirrhosis. In addition, 
Zhang et al reported that synchronous splenectomy and hepa-
tectomy improved the disease-free survival rate compared 
with hepatectomy alone (12). Although the clinical merits of 
splenectomy for patients with cirrhosis have been reported, 
the possible immunological advantages have not yet been fully 
explored.
In the present study, we examined the effects of splenectomy 
on the neutrophil-to-lymphocyte ratio (NLR), an indicator 
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of systemic inflammation and cancer outcomes (13,14), and 
phenotypes of various immune cells among peripheral blood 
mononuclear cells (PBMCs). Immune responses against 
viral- and tumor-associated antigens were also assessed and 
compared before and after splenectomy. Our results suggested 
that splenectomy might ameliorate the impaired immune status 
in patients with liver cirrhosis, possibly by reducing suppres-
sive cell fractions and enhancing the effector cell population 
and function, which could, at least in part, explain the mecha-
nisms responsible for clinical benefits of splenectomy.
Patients and methods
Patients. Eleven patients with liver cirrhosis and hyper-
splenism underwent hand-assisted laparoscopic splenectomy 
at the Department of Surgery of Kurume University Hospital. 
Six patients were male and five were female, with a median 
age of 65 years (range, 44-75 years). Five and six patients 
were classified as having Child‑Pugh class A and B liver 
disease, respectively. Ten patients were HCV-positive and 
the remaining patient had alcoholic cirrhosis. Six patients 
had HCC. We performed splenectomy in an attempt to either 
manage thrombocytopenia caused by hypersplenism and 
thus facilitate anti-HCC treatment by improving liver func-
tion (n=6) or to prevent further thrombocytopenia caused 
by interferon treatment in patients with HCV (n=5). The 
patients with HCC received simultaneous radiofrequency 
ablation to treat hepatic lesions. Because prevalence of 
portal thrombosis after splenectomy in patients with liver 
cirrhosis was high (7,15), we performed prophylactic antico-
agulation using danaparoid sodium and warfarin potassium 
to prevent portal thrombosis after splenectomy, as previ-
ously reported (7).
Along with careful clinical observations, the white blood 
cell (WBC), lymphocyte, neutrophil, and platelet counts 
were measured in the peripheral blood before and at 1, 3, and 
6 months after splenectomy. The NLR was defined as the 
absolute neutrophil count divided by the absolute lymphocyte 
count. The study was conducted in accordance with the provi-
sions of the Declaration of Helsinki and was approved by the 
Institutional Review Board at Kurume University Hospital. 
Before surgery, possible undesirable outcomes were explained 
to all patients involved in the study, and written informed 
consent was obtained from all patients.
Immune cell phenotypes. Immune cell phenotypes were 
determined by flow cytometry. A total of 30 ml of peripheral 
blood was serially obtained immediately before and at 1, 3, 
and 6 months after splenectomy. PBMCs were isolated by 
density gradient centrifugation with the Ficoll-Paque Plus 
(GE Healthcare, Uppsala, Sweden) and frozen until analysis. 
After thawing, PBMCs (5x105 cells) were suspended in 
phosphate-buffered saline (PBS) containing 2% fetal bovine 
serum (MP Biologicals, Solon, OH, USA) and incubated for 
30 min on ice with the appropriate dilution of antibodies. For 
analysis of CD4+ and CD8+ T cells and their naïve/memory 
subsets, PBMCs were stained with mouse anti-human CD4, 
mouse anti-human CD8, mouse anti-human CCR7, and mouse 
anti-human CD45RA monoclonal antibodies (mAbs). Since 
the available combination between mAbs and fluorescent dyes 
was limited in this multicolor flow cytometry panel, we could 
not completely compensate the spectral overlap. Therefore, 
nonlinear gating lines were set by using control samples, 
as previously reported (16). For analysis of gamma-delta 
(γδ) T, natural killer T (NKT), and natural killer (NK) cells, 
PBMCs were stained with mouse anti-human TCR γδ, mouse 
anti-human CD3, mouse anti-human CD16, and mouse 
anti-human CD56 mAbs. For analysis of Treg cells, PBMCs 
were stained with mouse anti-human CD4, mouse anti-human 
CD25, and mouse anti-human FoxP3 mAbs using the One 
Step Staining Human Treg FlowTM Kit (BioLegend, San Diego, 
CA, USA). For analysis of granulocytic myeloid-derived 
suppressor cells (MDSCs), PBMCs were stained with mouse 
anti-human CD11b, mouse anti-human CD15, and mouse 
anti-human CD33 mAbs (17). All mAbs were from BioLegend 
except for the anti-CD15 mAb (BD Biosciences, San Diego, 
CA, USA). The samples were run on a FACSCanto II analyzer 
(BD Biosciences), and the frequencies of each of the immune 
subsets were analyzed using FlowJo ver. 10 software (Tree 
Star, Ashland, OR, USA).
Immune responses to antigen peptides. To evaluate immune 
cell function, T-cell responses against viral- or tumor-associ-
ated antigen peptides were evaluated by an interferon gamma 
(IFN-γ) Enzyme-Linked ImmunoSpot (ELISPOT) assay with 
PBMCs before and after splenectomy in the enrolled patients 
whose PBMCs were available for analysis. The viral-asso-
ciated antigen peptide pool consisted of 23 different HLA 
class I-restricted peptides derived from cytomegalovirus, 
Epstein‑Barr virus, or influenza virus (CEF; Mabtech, Nacka 
Strand, Sweden). The CEF peptide pool contained 2 HLA-A1-, 
3 HLA-A2-, 3 HLA-A3-, 2 HLA-A11-, 1 HLA-A24-, 
1 HLA-A68-, 2 HLA-B7-, 4 HLA-B8-, 2 HLA-B27-, 
1 HLA-B35-, and 2 HLA-B44-restrcited peptides. The 
tumor-associated antigen peptide pool consisted of 20 different 
HLA class I-restricted peptides (KRM-20) as reported previ-
ously (18). The KRM-20 peptide pool contained 5 HLA-A2-, 
9 HLA-A24-, 3 HLA-A3 supertype-, 1 HLA-A24/A3 super-
type-, and 2 HLA-A24/A3 supertype/A26-restrcited peptides. 
PBMCs (1x105 cells/well) were incubated in round 96-well 
microculture plates (Thermo Fisher Scientific, Rochester, NY, 
USA) with 200 µl of medium (OpTmizer T Cell Expansion 
SFM; Life Technologies, Carlsbad, CA, USA) containing 
10% fetal bovine serum (MP Biologicals), interleukin 2 (20 
IU/ml; AbD Serotec, Kidlington, UK), and the peptide pools 
(CEF, 2 µg/ml; KRM-20, 10 µg/ml) for 7 days. After incuba-
tion, the cells (1-2x104 cells/well) were harvested and tested 
for their ability to produce IFN-γ in response to the corre-
sponding peptide pool (CEF, 2 µg/ml; KRM-20, 10 µg/ml). 
Antigen‑specific IFN‑γ secretion after 18 h of incubation was 
determined by the ELISPOT assay in accordance with the 
manufacturer's instructions (Mabtech), and spots were counted 
by an ELISPOT reader (CTL ImmunoSpot S5 Series; Cellular 
Technology, Ltd., Shaker Heights, OH, USA). Antigen‑specific 
T-cell responses were evaluated by the difference between the 
numbers of spots produced in response to each corresponding 
peptide pool and those produced without it.
Statistical analysis. Data are expressed as mean or median 
with standard deviation. The paired Student's t-tests was used 
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for comparison of percentages of lymphocytes and neutrophils 
in the WBC counts, neutrophil-to-lymphocyte ratios and 
immune cell phenotypes determined by flow cytometry. Since 
these analyses were exploratory, but not confirmatory, paired 
Student's t-tests was employed without considering adjust-
ment of multiplicity. The Wilcoxon signed rank test was used 
for comparison of spot numbers of antigen‑specific T cells 
determined by ELISPOT assay. A two‑sided significance level 
of 5% was considered statistically significant in all analyses. 
Statistical analyses were performed using SAS software 
version 9.4 (SAS Institute, Cary, NC).
Results
Clinical outcomes. The average weight of the excised spleen 
was 522±211 g. The average blood loss volume was 82±187 ml, 
and the average operation time was 235±74 min. Postoperative 
complications were portal thrombosis (n=1), ascites (n=1), 
bacterial colitis (n=1), and fever (n=1). Portal thrombosis was 
treated with anticoagulants. Bacterial infection and ascites 
were successfully treated with antibiotics and diuretics, 
respectively. No patients had fatal complications. Patients were 
discharged at 14±2.6 days.
The average platelet count before splenectomy was 
4.9±1.6x104/mm3, and the average WBC count was 
2633±947/mm3. Although the neutrophil count was signifi-
cantly higher only at 1 month after splenectomy (P=0.039), 
the lymphocyte count remained at higher levels at 1 month 
(P=0.004), 3 months (P<0.001), and 6 months (P<0.001). The 
percentage of neutrophils in WBC was significantly higher than 
that of lymphocytes in WBC before splenectomy (P<0.05). In 
contrast to a significant decrease in the percentages of neutro-
phils in WBC at 1 month (P=0.033), 3 months (P<0.001), and 
6 months (P=0.001) after splenectomy, those of lymphocytes 
in WBC significantly increased at 3 months (P<0.001) and 
6 months (P=0.005; Fig. 1A). The NLR significantly decreased 
at 3 months (P<0.001) and 6 months (P=0.008; Fig. 1B).
Changes in CD4+ and CD8+ T cells and their naïve/memory 
subsets. Fig. 2A shows a representative flow cytometry profile 
of CD4+ T cells, CD8+ T cells, and their naïve/memory 
subsets in PBMCs before and after splenectomy. As shown 
in Fig. 2B, the frequency of CD4+ T cells significantly 
decreased at 1 month (P=0.003), 3 months (P=0.001), and 
6 months (P=0.016) after splenectomy, while that of CD8+ 
T cells significantly increased at 3 months (P=0.004) and 
6 months (P=0.014). In addition, the frequencies of the naïve 
(CCR7+CD45RA+) and central memory (CCR7+CD45RA-) 
subset of CD4+ T cells significantly decreased at 1 month 
(P<0.001 and P=0.022, respectively), 3 months (P=0.001 and 
P=0.012, respectively), and 6 months (P<0.001 and P=0.023, 
respectively) after splenectomy. In contrast, that of the effector 
memory subset (CCR7-CD45RA-) significantly increased 
at 1 month (P=0.001), 3 months (P<0.001), and 6 months 
(P=0.001; Fig. 2C).
Similarly, in CD8+ T cells, the frequencies of the naïve 
(CCR7+CD45RA+) and central memory (CCR7+CD45RA-) 
subset significantly decreased at 1 month (P=0.007 and 
P=0.017, respectively), 3 months (P=0.010 and P=0.018, 
respectively), and 6 months (P=0.008 and P=0.008, respec-
tively) after splenectomy, whereas that of the effector memory 
subset (CCR7-CD45RA-) significantly increased after 1 month 
(P=0.003), 3 months (P=0.017), and 6 months (P=0.011; 
Fig. 2D).
Changes in γδ T, NKT, and NK cells. We also investigated 
the frequencies of γδ T, NKT, and NK cells among PBMCs 
before and after splenectomy. Fig. 3A shows a representa-
tive flow cytometry profile of γδ T, NKT and NK cells. As 
shown in Fig. 3B, the frequency of γδ T cells (CD3+ TCR 
γδ+) significantly increased at 1 month (P=0.039) and 
3 months (P=0.008) after splenectomy. In the same manner, 
the frequency of NKT cells (CD3+CD56+) tended to increase 
after 1 month (P=0.064) and 3 months (P=0.007; Fig. 3C). 
However, NK cells (CD3−D56+) showed a significant 
increase after 1 month (P=0.010), but not at any other time 
points (3 months, P=0.134; 6 months, P=0.210; Fig. 3D). 
The frequency of the CD56dimCD16+ NK cell subset tended 
to increase at 1 month (P=0.052), 3 months (P=0.017), and 
6 months (P=0.070) after splenectomy, whereas that of the 
Figure 1. Alterations in lymphocytes and neutrophils following splenectomy. (A) Percentages of lymphocytes and neutrophils in the white blood cell counts 
before and after splenectomy. (B) Neutrophil-to-lymphocyte ratio before and after splenectomy. The data are presented as the mean ± standard deviation. The 
percentages or ratios at the indicated time points after splenectomy were compared with those before splenectomy. *P<0.05 by paired Student's t-test compared 
with the data before splenectomy.
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CD56brightCD16dim/- NK cell subset tended to decrease after 
1 month (P=0.023), 3 months (P=0.068), and 6 months 
(P=0.069; Fig. 3E). We observed significant changes in γδ T, 
NKT, and NK cells only at the earlier two time points (1 and 
3 months), suggesting that they might represent a transient, 
but not continuous, response to splenectomy.
Changes in Treg cells and MDSC. The frequencies of 
inhibitory immune cell subsets, including Treg cells and 
MDSCs, were further examined in PBMCs before and after 
splenectomy. Fig. 4A shows a representative flow cytometry 
profile of Treg cells. As shown in Fig. 4B, the frequency of 
Treg cells (CD4+CD25+FoxP3+) among PBMCs transiently 
decreased 3 months (P=0.045) after splenectomy, but not at 
the other time points (1 month, P=0.782; 6 months, P=0.416). 
Fig. 4C shows a representative flow cytometry profile of 
granulocytic MDSCs. As shown in Fig. 4D, the frequency of 
granulocytic MDSCs (CD11b+CD15+CD33+) was significantly 
lower at 3 months (P=0.022) and 6 months (P=0.045) after 
splenectomy. In contrast, the frequency of monocytic MDSCs 
(CD14+HLA-DR-/low) was not significantly affected (data not 
shown).
Evaluation of T‑cell responses to viral‑ and tumor‑associated 
antigens. To evaluate the effects of splenectomy on immune 
function, we examined T-cell responses to viral-associated 
(n=8) and tumor-associated (n=5) antigens using an IFN-γ 
ELISPOT assay with PBMCs before and after splenectomy. 
Fig. 5A and B show representative results of the assay in 
response to both viral- and tumor-associated antigens. In 
five of eight patients with liver cirrhosis, PBMCs after sple-
nectomy showed higher numbers of IFN-γ-producing cells 
after stimulation with the viral-associated antigen peptide 
pool (CEF) compared with those before splenectomy. As 
shown in Fig. 5C, the spot numbers of CEF‑specific cells after 
6 months of splenectomy were significantly higher than those 
before splenectomy (P=0.031). In addition, when PBMCs were 
stimulated with the tumor-associated antigen peptide pool 
(KRM-20), more IFN-γ-producing T cells were detected after 
splenectomy in two of five patients with cirrhosis. As shown 
in Fig. 5C, the spot numbers of KRM‑20‑specific cells after 
6 months of splenectomy tended to be higher than those before 
splenectomy, although not statistically significant (P=0.125), 
possibly due to the small sample size and the high standard 
deviation.
Figure 2. Alterations in CD4+ and CD8+ T cells and their naïve/memory subsets following splenectomy. (A) Representative flow cytometry profile of 
naïve/memory subsets in CD4+ and CD8+ T cells. (B) Frequencies of CD4+ and CD8+ T cells before and after splenectomy. Frequencies of naïve/memory 
subsets in (C) CD4+ T cells or (D) CD8+ T cells before and after splenectomy. The data are presented as the mean ± standard deviation. The frequencies at the 
indicated time points after splenectomy were compared with those before splenectomy in each of the naïve/memory subsets. *P<0.05 by paired Student's t-test 
compared with the data before splenectomy. CM, central memory; EM, effector memory; CD, cluster of differentiation; CCR7, C-C chemokine receptor type 
7; SSC, side scatter; FSC, forward scatter.
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Discussion
The current study demonstrated that splenectomy significantly 
increased the frequencies of immune cells with effector prop-
erties such as CD8+ T cells, γδ T cells, NKT cells, and NK 
cells, but significantly decreased those with suppressive prop-
erties such as Treg cells and MDSCs. In addition, the immune 
responses against viral- and tumor-associated antigens were 
augmented after splenectomy. These findings suggest that 
splenectomy might ameliorate the impaired immune status in 
cirrhotic patients with hypersplenism.
The NLR is one of the markers used to identify systemic 
inflammation, which is associated with the development, 
progression, and prognosis of various benign and malig-
nant diseases. A higher NLR reflects increased production 
and secretion of pro‑inflammatory cytokines and vascular 
endothelial growth factor by neutrophils in the circulation, 
resulting in vascular invasion, seeding, and growth of malig-
nant cells (13,14,19,20). For example, an elevated NLR has 
been reported to correlate with the tumor burden, recurrence, 
and survival in patients with colorectal cancer, colorectal 
liver metastasis, HCC, gastric cancer, renal cancer, and 
pancreatic cancer (13,14,19-21). The NLR has also been found 
to reflect the severity of other diseases, including sepsis, 
cardiovascular abnormalities, and diabetes mellitus (22). The 
present study showed that the NLR was significantly lower 
at 3 and 6 months after splenectomy. Similarly, reduction of 
the NLR, which was correlated with better prognosis, was 
observed after splenectomy in our previous study of patients 
with HCC (7).
Figure 3. Alterations in γδ T, NKT and NK cells after splenectomy. (A) Representative flow cytometry profile of γδ T, NKT and NK cells. Frequencies of 
(B) γδ T cells, (C) NKT cells, (D) NK cells or (E) NK cell subsets defined by CD16 and CD56 expressions before and after splenectomy. Data are presented 
as the mean ± standard deviation. The frequencies at the indicated time points after splenectomy were compared with those before splenectomy. *P<0.05 by 
paired Student's t-test compared with the data before splenectomy. NKT, natural killer T; NK, natural killer; CD, cluster of differentiation; SSC, side scatter; 
FSC, forward scatter; TCR, T-cell receptor.
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Patients with cirrhosis have a higher CD4+/CD8+ T cell 
ratio because of an increase in CD4+ T cell frequency together 
with a decrease in CD8+ T cell frequency (3). Since CD8+ 
T cells play crucial roles in anti-infection and anti-tumor 
immune responses, patients with liver cirrhosis are considered 
to be immunocompromised in part due to reduced CD8 cells, 
which might lead to higher incidences of bacterial infection 
and HCC development/recurrence (3,4). The current study 
demonstrated that splenectomy lowered the CD4+/CD8+ T-cell 
ratio by decreasing the CD4+ T-cell frequency and increasing 
the CD8+ T-cell frequency, which may potentially enhance the 
anti-infection and anti-tumor immune responses. In addition, 
we detected an increase in effector memory T-cell subsets and 
a reduction in naïve and central memory subsets after splenec-
tomy. Naïve T cells initiate immune responses to new antigens, 
while memory T cells (central memory and effector memory 
cells) respond to previously encountered antigens (23). 
Central memory cells are restricted to the lymphoid tissue 
and blood, whereas effector memory cells broadly migrate 
between peripheral tissues, blood, and the spleen, and provide 
immediate protection against pathogens (24). Such changes 
in naïve/memory T-cell subsets in this study might have 
resulted from accelerated antigen‑specific immune responses 
after splenectomy (23,25,26). Indeed, in the current study, 
T-cell-mediated IFN-γ production in response to viral- and 
tumor-associated antigens was shown to increase after sple-
nectomy in some patients with cirrhosis. Similarly, it has been 
suggested that splenectomy in patients with cirrhosis might 
improve their impaired immune status by increasing IFN-γ 
production and reducing programmed cell death protein 1 
(PD-1)-expression in peripheral CD4 T cells (27,28).
This is the first study to show a decrease in MDSCs after 
splenectomy in patients with cirrhosis. Recent studies have 
shown that MDSCs are closely associated with suppressive 
immune conditions (29) and that a high MDSC count before 
treatment is a negative prognostic factor for patients with 
HCC undergoing hepatic arterial infusion chemotherapy (30). 
In tumor-bearing animal models, immature myeloid cells, 
including MDSCs, were found to accumulate in the spleen, the 
removal of which inhibited the growth and progression of liver 
cancer and prolonged animal survival (31). Because MDSCs 
also inhibit cytotoxic T-cell activation (25,26,31), the reduced 
number of MDSCs in our patients after splenectomy might 
enhance immune competence.
The current study also demonstrated for the first time that 
CD4+CD25+FoxP3+ Treg cells decreased after splenectomy 
in the peripheral circulation of patients with cirrhosis. Treg 
cells are another subset of immune suppressors that play an 
Figure 4. Alterations in Treg cells and MDSCs after splenectomy. (A) Representative flow cytometry profile of Treg (CD4+CD25+FoxP3+) cells. (B) Frequencies 
of Treg cells before and after splenectomy. (C) Representative flow cytometry profile of granulocytic MDSCs (CD11b+CD15+CD33+). (D) Frequencies of 
granulocytic MDSCs before and after splenectomy. Data are presented as the mean ± standard deviation. The frequencies at the indicated time points after 
splenectomy were compared with those before splenectomy. *P<0.05 by paired Student's t-test compared with the data before splenectomy. Treg, regulatory T; 
MDSCs, myeloid-derived suppressor cells; CD, cluster of differentiation; FoxP3, forkhead box protein P3; SSC, side scatter; FSC, forward scatter.
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important role in the development and progression of various 
diseases such as autoimmune disease, viral infection, and 
cancer (29). In a previous study, the frequency of Treg cells 
was elevated in patients with HCV+ liver cirrhosis (32). A 
higher frequency of Treg cells was shown to be significantly 
associated with enhanced tumor growth of HCC in patients 
undergoing intra-arterial chemotherapy (33). The spleen is 
also reportedly a major source of Treg cells in patients with 
splenomegaly (34). MDSCs, the numbers of which decreased 
after splenectomy in this study, promote de novo development 
and induction of Treg cells (29). Considering all of these find-
ings, splenectomy appears to enhance the immune response 
through reduction of Treg cells and MDSCs in the spleen and 
peripheral blood.
In contrast, NK cells play an important role in anti-viral 
and anti-tumor defenses. NK cells perform various effector 
functions, including production of IFN-γ, activation of tumor 
antigen‑specific CD8+ T cells, and initiation of perforin-medi-
ated cytolysis of tumor cells (35,36). Other researchers have 
reported that in patients with HCV+ liver cirrhosis, NK cells 
decreased in number and were correlated with HCC develop-
ment (37), and that HCV downregulated NK cell function 
via viral serine protease NS3 (38). In the current study, the 
frequency of NK cells significantly increased 1 month after 
splenectomy. In particular, the number of cells in the CD56dim 
NK cell subset, which exhibited more powerful cytotoxic 
activity than CD56bright NK cells (39), was significantly elevated 
after splenectomy. Splenectomy in HCV-positive patients with 
cirrhosis augmented the activity of NK cells (36). A significant 
increase in both the percentage and activity of NK cells after 
splenectomy has also been reported by other researchers (40). 
Because MDSCs reportedly suppress the production of IFN-γ 
by NK cells (41), it is possible that reduction of MDSCs after 
splenectomy may increase the NK cell number and function to 
augment protective immunity.
Recently, oral thrombopoietin receptor agonists have been 
reported to stimulate thrombopoiesis, and potentially improve 
pancytopenia in cirrhotic patients (42,43). They transiently 
increase platelet counts for a limited period (42,43), while sple-
nectomy in cirrhotic patients improve hypersplenism, including 
increase of platelet and white blood cell counts, for a long 
period (7,8). In addition, splenectomy not only has the clinical 
benefits, such as improvement of liver function and reduction 
of portal venous pressure (7-11), but also may contribute to 
immunological benefits, based on our study and others (27,28). 
It would be interesting to examine immune status after treat-
ment with oral thrombopoietin receptor agonists and compare 
it with that after splenectomy in cirrhotic patients.
Partial splenic embolization (PSE) via catheter interven-
tion is also known to be an effective alternative to splenectomy 
that is less invasive than surgery. Interestingly, Matsukiyo et al 
recently reported that PSE not only improve leukopenia and 
thrombocytopenia but also induce activation of CD4+ T cells, 
including Th1 and Th2 cells, in patients with cirrhosis and 
thrombocytopenia (44). Because the current study did not 
address Th1 and Th2 cytokine expression and their balance in 
CD4+ T cells, it would be interesting to examine them before 
and after splenectomy and compare them with those after 
PSE in cirrhotic patients in future studies. Matsukiyo et al 
also demonstrated that Treg cells, which were identified as 
CD4+CD25highCD127low, did not significantly change after 
PSE (44), whereas we showed that Treg cells, which were 
identified as CD4+CD25+FoxP3+, decreased after splenec-
tomy in patients with cirrhosis. Such discrepancy might be 
explained by the different definition of Treg cells, as previ-
ously reported (45).
Figure 5. T-cell responses to viral- and tumor-associated antigens. T-cell responses to viral- and tumor-associated antigens were evaluated by IFN-γ ELISPOT 
assay with PBMCs before and after splenectomy. (A) Representative result of the IFN-γ ELISPOT assay with PBMCs (1x104 cells/well) stimulated with or 
without the viral-associated CEF peptide pool in a patient with cirrhosis before and after splenectomy. (B) Representative result of IFN-γ ELISPOT assay with 
PBMCs (1.3x104 cells/well) stimulated with or without the tumor-associated KRM-20 peptide pool in a patient with cirrhosis before and after splenectomy. The 
numbers of spots produced by antigen‑specific T‑cell responses are shown. (C) Spot numbers of CEF‑ or KRM‑20‑specific cells after 6 months of splenectomy 
were compared with those before splenectomy by the Wilcoxon signed rank test. Data are presented as the median with standard deviation. IFN-γ, interferon-γ; 
PBMCs, peripheral blood mononuclear cells.
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In summary, the current study suggested that splenectomy 
might ameliorate the impaired immune status of patients with 
cirrhosis, possibly by reducing suppressive cell fractions and 
enhancing the effector cell population and function. To our 
knowledge, this is the first study to comprehensively examine 
the effects of splenectomy on the NLR as well as the immu-
nological phenotypes and responses in peripheral blood. 
However, this study has several limitations. First, this was a 
small study comprising patients with different disease states. 
Second, although changes in the immune cell phenotypes 
were precisely characterized, the immune functions of each 
cell subset were not examined in detail. Third, the enrolled 
patients were followed only for a limited period of time after 
splenectomy. Further studies with more patients and longer 
follow-ups are required.
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